论文部分内容阅读
目的观察孟鲁司特治疗轻度儿童哮喘的疗效。方法选取2010年2月～2012年2月我院门诊收治的40例轻度哮喘患儿,服用孟鲁司特钠咀嚼片,对治疗前、治疗4周、8周和12周进行基本情况评分,测定呼气峰流速(PEFR)和第一秒用力呼气容积(FEV1)进行比较。结果患儿就诊后,基本情况评分逐渐下降,PEFR、FEV1逐渐上升,与治疗前比较,具有显著差异性(P<0.05),5例患儿出现不良反应,对症处理后,均能继续完成整个治疗。β2受体激动剂随着孟鲁司特的使用时间延长,其使用率越少。结论应用孟鲁司特治疗轻度儿童哮喘作用佳、依从性好、副作用小,是值得临床推广使用。
Objective To observe the efficacy of montelukast in the treatment of mild asthma in children. Methods Forty patients with mild asthma admitted from our hospital from February 2010 to February 2012 were enrolled in this study. The montelukast sodium chewable tablets were taken before treatment, 4 weeks, 8 weeks and 12 weeks after treatment. , The peak expiratory flow rate (PEFR) and the first second forced expiratory volume (FEV1) were compared. Results After treatment, the score of basic condition gradually decreased and PEFR and FEV1 gradually increased. Compared with those before treatment, there was significant difference (P <0.05). In 5 cases, adverse reactions were observed and all the patients were able to finish the whole treatment. β2 receptor agonists with montelukast use of time, the less its use. Conclusion Montelukast treatment of mild asthma in children with good effect, good compliance, small side effects, is worthy of clinical promotion and use.